The WSJ via Fierce Biotech says don't be surprised if Sanofi takes its time in reaching a deal with Genzyme. The Company is known to be methodical and several large shareholders don't want to overpay. Genzyme on the other hand is looking for top dollar and certainly is in no hurry to sell until it gets a higher offer. Besides, there are constant rumors of others who may enter the bidding - although none have really surfaced in the flesh as far as I can tell.
In the meantime, this is good fodder for the rumor mill and blogs like this one.
Posted by Bruce Lehr August 19th 2010.